GRCE (Grace Therapeutics) Short Interest


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.33
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GRCE vs PSTV, ATNM, NNVC: Short Interest Comparison

For the Biotechnology subindustry, Grace Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grace Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Short Interest falls into.


GRCE
31GF Score
Grace Therapeutics Inc GRCE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.33
Price